Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

AstraZeneca’s lung cancer combo fails in phase III trial AstraZeneca’s lung cancer combo of Imfinzi (durvalumab) plus tremelimumab has failed to deliver desired results in a phase III trial, called ARCTIC, in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who had more than two prior treatments.
Contract Research & Services > Clinical Trials > News
Prothena scraps development of AL amyloidosis drug By PBR Staff Writer
Prothena is stopping the development of AL amyloidosis treatment NEOD001 following unfavorable results in the phase 2b Pronto study.
Contract Research & Services > Clinical Trials > News Helperby Therapeutics’ combination antibiotic therapy is effective against WHO critical priority pathogen in phase 1 study Helperby Therapeutics has announced Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
Helperby Therapeutics’ combination antibiotic therapy is effective against WHO critical priority pathogen in phase 1 study
Helperby Therapeutics has announced Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.
Contract Research & Services > Clinical Trials > News
Boehringer Ingelheim, Lilly, University of Oxford to study empagliflozin in chronic kidney disease
Boehringer Ingelheim and Eli Lilly and Company have entered into an academic collaboration with the University of Oxford to assess the effects of Jardiance (empagliflozin) on heart and kidney disease in adults with chronic kidney disease.
Contract Research & Services > Clinical Trials > News
Merck’s Keytruda significantly decreases risk of disease recurrence in melanoma study
Merck has reported results from the Phase 3 EORTC1325/KEYNOTE-054 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma.
Contract Research & Services > Clinical Trials > News
AstraZeneca's Tagrisso shows sustained PFS in phase 3 lung cancer trial
By PBR Staff Writer
AstraZeneca said that Tagrisso (osimertinib) in a first line setting has shown significant progression-free survival (PFS) benefit that was preserved through subsequent lines of therapy in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
Personalized tumor vaccine yields promising results in pilot trial
A new type of cancer vaccine has shown promise in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of Pennsylvania.
Contract Research & Services > Clinical Trials > News
Futility forces Pfizer to stop phase 3 trial of Inlyta for recurrent renal cell carcinoma
By PBR Staff Writer
The independent data monitoring committee (DMC) has recommended the termination of a phase 3 clinical trial assessing Pfizer's Inlyta (axitinib) as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy due to futility.
Contract Research & Services > Clinical Trials > News
UK Prime Minister unveils plans to tackle prostate cancer
By PBR Staff Writer
UK Prime Minister Theresa May has announced £75m of funding to support new research for early diagnosis and treatment of prostate cancer.
Contract Research & Services > Clinical Trials > News
AbbVie’s upadacitinib succeeds in phase 3 rheumatoid arthritis trial
By PBR Staff Writer
AbbVie’s rheumatoid arthritis drug upadacitinib (15mg, once-daily) has met its primary and secondary endpoints in the phase 3 Select-Compare clinical study.
Contract Research & Services > Clinical Trials > News
What's Hot at VFE2018 Softigel by Procaps
At this moment, what´s moving market growth are basically 3 aspects: - Aging population, were we see each day that senior consumers do not want to be defined by their age and wish to maintain their same active Lifestyle. - The FITNESS move, with consumers who are in search of preventive measures, instead of reactive measures in order to avoid future health problems. - And SELF-CARE: Since consumers are everyday more concerned with their wellbeing, new and more specialized Supplements need to be developed.
Contract Research & Services > Clinical Trials > Press Releases
View all Clinical Trials news or find news targeted to your interests